(Received for publication March 1, 1995) The macrolide antibiotic erythromycin A 1 is a potent Gram-positive antibacterial agent. Pioneering studies by Omura et al., 1] demonstrated that its 8,9-anhydro-6,9-hemiacetal (enol ether) derivative 2 has diminished antibacterial activity but is a potent motilin receptor agonist (motilide). 2) As such 2 induces contractions in the smooth muscle of the gastrointestinal (GI) tract of dog and is potentially useful as a GI prokinetic agent.
In an effort to extend the SARof the motilides, we decided to determine the effect of C-12 deoxygenation of 2 on both antibacterial and prokinetic activities. The deoxy congener with the natural (R) configuration at C-12 4 is synthetically accessible3) from erythromycin B 3, but in order to obtain the (S')-epimer, we had to devise methodology for selective deoxygenation of 1. The 12-OH of 1 is hindered and inaccessible selectively, therefore our strategy was to take advantage of the reactivity and^^-orientation of the vicinal ll-OH to prepare an 1 1,12-cyclic thionocarbonate. In accordance with Barton and McCombie,4) a tributylstannyl radical should attack the thiocarbonyl group to generate a radical intermediate which, in this case, could fragment to the secondary radical at C-ll or the tertiary radical at C-12. Since tertiary radicals are more stable than secondary radicals and react faster in both fragmentation and hydrogen abstraction reactions,5'6) we hoped that the Barton-McCombie deoxygenation would be selective for C-12, to give epimeric 12-deoxy congeners.
Thus the 2'-OH and 4"-OH groups were sequentially and selectively protected with an acetyl and a benzyloxycarbonyl group respectively (Scheme 1) to provide 5.
Treatment of 5 with thiophosgene gave the 1 1,12-cyclic thionocarbonyl-6,9-hemiacetal intermediate 6. Deoxygenation of 6 with tri-vV-butyltin hydride was regioselective for C-12, but to our surprise, enol ether 8 with the unnatural (S)-configuration at C-12 was the exclusive deoxygenation product. Hence conditions for the deoxygenation had also resulted in the elimination of the hemiacetal hydroxy group at C-9 of 6 to generate the enol eher. On the other hand, prior conversion of 6 to enol ether 7, followed by treatment with tri-rc-butyltin hydride afforded compound 9 with the natural configuration at C-12. These results also demonstrate that formation of the enol ether from 6 occured after the C-12 deoxygenation and that the hemiacetal OH-groupplayed a role in directing the stereoselectivity of the deoxygenation. Removal of the protecting groups in 8 and 9 by treatment with methanol followed by hydrogenolysis showed NOEs from 21-H to 10-H and to ll-H. There was also an NOEbetween ll-H and 13-H, consistent with conformation 12. Conformation 12 is similar to the X-ray crystallographic structure reported7) for (9R)-9-dihydro-6,9-anhydroerythromycin A. This conformation may have been less favored in the case of8, since it would have put C-20 and C-21 in a 1,3-diaxial relationship. The activity of 10 was compared to 4 in a rabbit duodenal smooth muscle contractility assay, which serves as an in vitro evaluation of prokinetic potency. Compound 10 was much weaker (pED50=7.0) than 4 (pED5O=8.7). Hence, epimerization at C-12 with concomitant conformational change around the C-10 to C-13 region of the macrolactone resulted in a significant decrease in prokinetic activity. The in vitro antibacterial activity of 10 as well as its 9-ketone analog (12-This manuscript is a special contribution in honour of Professor Satoshi Omura's 60th birthday. 
